Please assess the completion status of the following clinical trial:

Trial Title: Does Oral Desogestrel Prior to Insertion of the Etonogestrel Subdermal Implant Improve Continuation Rate at One Year?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Women age of 18 - 42 years~* Interested in the use of ESI~* Accepting to have 90 days pre-treatment with OD~* Signed informed consent~Exclusion criteria:~* Pregnancy~* Lactation,~* vaginal bleeding of unknown origin,~* wish to become pregnant,~* weight over 80 kg,~* history of deep vein thrombosis/Pulmanory embolism,~* hypertension,~* Diabetes or other metabolic diseases,~* coagulation disorders,~* severe hepatic disorder,~* history of breast/endometrial cancer,~* known hypersensitivity to study drug,~* current treatment with enzyme inducing drugs (e.g.: phenytoin, carbamazepine, phenobarbital, etc.)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: t

Study Arms:
- ESI (Implanon NXT® subdermal implant) (Type: ACTIVE_COMPARATOR): In this group, the implant was inserted immediately after thorough explanations of the potential side effects and possible adverse events
- DSG + ESI(Desogestrel +Implanon NXT® subdermal implant) (Type: EXPERIMENTAL): In this group, patients were given a 3 months' supply of 75µg of DSG to be started immediately after which insertion of an ESI was proposed. Similarly, explanations of the potential side effects and possible adverse events were presented to the patient before treatment initiation.

Based on this trial design, predict the completion outcome and termination type (if applicable).